Comparative Pharmacology
Head-to-head clinical analysis: ADCIRCA versus AVANAFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADCIRCA versus AVANAFIL.
ADCIRCA vs AVANAFIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-5 (PDE5) inhibitor; increases cGMP in pulmonary vascular smooth muscle, leading to vasodilation.
Selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing nitric oxide-mediated relaxation of smooth muscle in the corpus cavernosum, increasing cGMP levels, and promoting penile erection.
10 mg orally three times daily.
100 mg orally once daily, taken 30-60 minutes before sexual activity. Maximum dosing frequency: once daily.
None Documented
None Documented
Terminal half-life: 10–15 hours in healthy adults; prolonged in hepatic impairment (Child-Pugh B/C: up to 30 hours); clinical context: supports twice-daily dosing
Clinical Note
moderateAvanafil + Torasemide
"Avanafil may increase the antihypertensive activities of Torasemide."
Clinical Note
moderateAvanafil + Travoprost
"Avanafil may increase the antihypertensive activities of Travoprost."
Clinical Note
moderateAvanafil + Unoprostone
"Avanafil may increase the antihypertensive activities of Unoprostone."
Clinical Note
moderateAvanafil + Hydrochlorothiazide
"Avanafil may increase the antihypertensive activities of Hydrochlorothiazide."
Terminal elimination half-life approximately 6-8 hours. Clinical context: Supports once-daily dosing; steady-state reached within 5 days with no accumulation at FDA-approved dose.
Renal: ~70% (metabolites and unchanged drug), Fecal: ~20%, Biliary: minor
Primarily hepatic metabolism via CYP3A4 and CYP2C9, with metabolites excreted in feces (approximately 82-90%) and urine (approximately 6-8% as unchanged drug and minor metabolites).
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor